COLD + SINUS DAYTIME TABLET
Država: Kanada
Jezik: angleščina
Source: Health Canada
Lastnosti izdelka
(SPC)
19-10-2020
Nekateri dokumenti za ta izdelek trenutno niso na voljo, pošljete lahko zahtevo v našo stranko in obvestili vas bomo takoj, ko jih bomo lahko pridobili.
Pošlji zahtevo.
Pošlji zahtevo.
Aktivna sestavina:
IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE
Dostopno od:
VITA HEALTH PRODUCTS INC
Koda artikla:
M01AE51
INN (mednarodno ime):
IBUPROFEN, COMBINATIONS
Odmerek:
200MG; 30MG
Farmacevtska oblika:
TABLET
Sestava:
IBUPROFEN 200MG; PSEUDOEPHEDRINE HYDROCHLORIDE 30MG
Pot uporabe:
ORAL
Enote v paketu:
10/20/24/40/50/72/96/100
Tip zastaranja:
OTC
Terapevtsko območje:
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Povzetek izdelek:
Active ingredient group (AIG) number: 0222394001; AHFS:
Status dovoljenje:
APPROVED
Datum dovoljenje:
2011-02-08
Lastnosti izdelka
PRODUCT MONOGRAPH
COLD + SINUS DAYTIME
Ibuprofen and Pseudoephedrine Hydrochloride Tablets USP
Ibuprofen 200 mg, Pseudoephedrine Hydrochloride 30 mg
Caplets
Analgesic/Antipyretic/Nasal Decongestant
COLD + SINUS NIGHTTIME
Ibuprofen 200 mg, Pseudoephedrine Hydrochloride 30 mg
and Chlorpheniramine Maleate 2 mg
Tablets
Analgesic/Antipyretic/Nasal Decongestant/Antihistamine
Vita Health Products Inc.
Date of Revision:
150 Beghin Avenue
October 19, 2020
Winnipeg, Manitoba Canada, R2J 3W2
Control # 239435
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
3
SUMMARY PRODUCT INFORMATION
..............................................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................................
5
ADVERSE REACTIONS
.......................................................................................................................
13
DRUG INTERACTIONS
........................................................................................................................
23
DOSAGE AND ADMINISTRATION
....................................................................................................
27
OVERDOSAGE
......................................................................................................................................
28
ACTION AND CLINICAL PHARMACOLOGY
..................................................................................
31
STORAGE AND STABILITY
...............................................................................................................
36
SPECIAL HANDLING INSTRUCTIONS
....................................
Preberite celoten dokument
